Page last updated: 2024-11-12

7-spiroindanyloxymorphone

Description

7-spiroindanyloxymorphone: a delta opioid receptor agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44444966
CHEMBL ID399708
SCHEMBL ID12013205
MeSH IDM0220541

Synonyms (17)

Synonym
7-(spiroindano)oxymorphone
CHEMBL399708 ,
7-(2'-spiroindanyl)oxymorphone
7-spiroindanyloxymorphone
spiroindanyloxymorphone
7-(2''-spiroindanyl)oxymorphone
bdbm50297170
spiro(6h-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2h)inden)-5(4ah)-one, 1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methyl-, (4ar-(4aalpha,7aalpha,8alpha,9calpha))-
35uf85t692 ,
150380-34-0
unii-35uf85t692
1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methylspiro(6h-8,9c-(iminoethano)phenanthro(4,5-bcd)furan-6,2'-(2h)inden)-5(4ah)-one (4ar-(4aalpha,7aalpha,8alpha,9calpha))-
SCHEMBL12013205
(1's,5'r,13'r,17's)-10',17'-dihydroxy-4'-methyl-1,3-dihydro-12'-oxa-4'-azaspiro[indene-2,15'-pentacyclo[9.6.1.0{1,13}.0{5,17}.0{7,18}]octadecane]-7',9',11'(18')-trien-14'-one
spiro[6h-8,9c-(iminoethano)phenanthro[4,5-bcd]furan-6,2'-[2h]inden]-5(4ah)-one, 1',3',7,7a,8,9-hexahydro-3,7a-dihydroxy-12-methyl-, (4ar,7as,8r,9cs)-
7-spiro[indanyloxymorphone]
(4r,4as,7ar,12bs)-3-methyl-4a,9-bis(oxidanyl)spiro(1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro(3,2-e)isoquinoline-6,2'-1,3-dihydroindene)-7-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.01060.00010.579710.0000AID141515
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.01060.00011.48339.1400AID141515
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.01060.00010.68688.2600AID141515
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.01060.00010.66618.2600AID141515
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.01060.00010.58908.2600AID141515
Delta-type opioid receptorMus musculus (house mouse)Ki0.01780.00000.53939.4000AID149085; AID149086; AID149094
Kappa-type opioid receptorMus musculus (house mouse)Ki3.00000.00030.35942.7500AID148319
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.08210.00000.38458.6000AID152386; AID152388; AID152389
Kappa-type opioid receptorRattus norvegicus (Norway rat)Ki0.27830.00000.18683.9500AID148584; AID148585; AID148586
Mu-type opioid receptorHomo sapiens (human)Ki0.08410.00000.419710.0000AID152081; AID152386
Delta-type opioid receptorHomo sapiens (human)Ki0.04040.00000.59789.9300AID147827; AID150038; AID150098; AID152386
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.58800.00000.20186.4240AID149555; AID430090
Kappa-type opioid receptorHomo sapiens (human)Ki1.57700.00000.362410.0000AID148718; AID152386
Mu-type opioid receptorMus musculus (house mouse)Ki0.01400.00000.12281.3000AID151270
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.01060.00000.27869.0000AID141515; AID430088
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorRattus norvegicus (Norway rat)Activity0.00840.00000.11931.2200AID310939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID141633Antinociceptive activity at mu opioid receptor from beta-funaltrexamine (beta-FNA) at the dose of 10 umol/kg (sc)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID430089Displacement of [3H]NTI from Hartley guinea pig delta opioid receptor by liquid scintillation counter2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative.
AID149104Antinociceptive potency at Opioid receptor delta 1 antagonist 7-benzylidenenaltrexone (BNTX) at the dose of 1.3 umol/kg (sc)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID79053Antagonist activity against electrically stimulated guinea pig ileum using ethylketazocine (EK) as kappa opioid receptor agonist1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID152081The compound tested for agonistic activity against Opioid receptor mu 1 using [3H]- DAMGO as the radioligand.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID147830Antinociceptive activity at Opioid receptor delta 2 antagonist naltriben (NTB) at the dose of 1.3 umol/kg (sc)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID152386Displacement of [3H]- diprenorphine from mu-K303E-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID149555selective binding affinity against kappa opioid receptor, using [3H]U-69593 as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID149094Inhibition of [3H]-NTI binding to Opioid receptor delta 1 from mouse brain membranes.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID430088Displacement of [3H]DAMGO from Hartley guinea pig mu opioid receptor by liquid scintillation counter2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative.
AID310938Agonist activity at rat delta opioid receptor expressed in C6 cells assessed as stimulation of [35S]GTP-gamma-S binding relative to BW373U862007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID133509Antinociceptive activity at kappa opioid receptor antagonist norbinaltorphimine (norBNI) at the dose of 12 umol/kg (sc)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID150098The compound tested for agonistic activity against Opioid receptor delta 1 using [3H]- NT1 as the radioligand.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID148584Displacement of [3H]diprenorphine from k-E297A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID114324Antinociceptive potency in mice using the tail-flick test on icv administration.1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID149472Antagonistic activity expressed as IC50 ratio in Opioid receptor mu 1 in electrically stimulated guinea pig ileum(GPI)1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
AID79054Antagonist activity against electrically stimulated guinea pig ileum using morphine (M) as mu opioid receptor agonist1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID148667Ability to inhibit binding of DADLE to Opioid receptor delta 1 was determined using mouse vas deferens; e = indicates not determined1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID79372Agonist activity expressed as percent inhibition of contraction of electrically stimulated guinea pig ileal longitudinal muscle at a concentration of 1 uM1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID151270Inhibition of [3H]DAMGO binding to Opioid receptor mu 1 from mouse brain membranes.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID148718The compound tested for agonistic activity against Opioid receptor kappa 1 as the [3H]- U-69,594 radioligand.1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID148695Ability to inhibit binding of ethylketazocine to Opioid receptor kappa 1 was determined using guinea pig ileal longitudinal muscle1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID148319Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 from mouse brain membranes.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID430090Displacement of [3H]U69493 from Hartley guinea pig kappa opioid receptor by liquid scintillation counter2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative.
AID150038Selective binding affinity against Opioid receptor delta 1, using [3H]DPDPE as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID148586Displacement of [3H]diprenorphine from opioid receptor kappa 1 expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID79207Compound was tested for agonistic activity on the electrically stimulated guinea pig ileum (GPI) at 1 uM1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID149086Displacement of [3H]- diprenorphine from delta-W284E-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148585Displacement of [3H]diprenorphine from k-Y312A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID147827Selective binding affinity against Opioid receptor delta 2, using [3H]DSLET as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID132332Agonist vas deferens(MVD)1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
AID138336Agonist activity expressed as inhibitory concentration against contraction of electrically stimulated mouse vas deferens1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID141515selective binding affinity against mu opioid receptor, using [3H]DAMGO as radioligand1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists.
AID152389Displacement of [3H]- diprenorphine from mu-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID149874Ability to inhibit binding of morphine to Opioid receptor mu 1 was determined using guinea pig ileal longitudinal muscle1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
AID138341Compound was tested for agonistic activity on the electrically stimulated mouse vas deferens (MVD)1997Journal of medicinal chemistry, May-23, Volume: 40, Issue:11
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
AID152388Displacement of [3H]- diprenorphine from mu-W318A-receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
AID148698Antagonistic activity expressed as IC50 ratio against ethylketazocine (EK) Opioid receptor kappa 1 in smooth muscle preparations1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
AID310939Displacement of [3H]naltrindole from rat delta opioid receptor expressed in C6 cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID78077Agonist activity (ability to decrease the twitch height of the electrically stimulated smooth muscle) in electrically stimulated guinea pig ileum(GPI)1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
AID149085Displacement of [3H]- diprenorphine from delta receptor expressed in HEK 293 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (58.33)18.2507
2000's5 (41.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
chemdatabank.com